Targeting specific immune cells to treat autoimmune diseases
Targeting T cell Subsets in Autoimmune Disease
This study is looking at how certain immune cells contribute to autoimmune diseases like IgG4-related disease, and it’s testing a new treatment called elotuzumab to see if it can help improve outcomes for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11084510 on NIH RePORTER |
What this research studies
This research focuses on understanding and treating autoimmune diseases by targeting specific subsets of T cells and B cells involved in the disease process. The team at Massachusetts General Hospital combines clinical and laboratory expertise to investigate the role of these immune cells in conditions like IgG4-related disease. They are conducting clinical trials using a monoclonal antibody called elotuzumab, which targets a specific marker on these immune cells, aiming to improve treatment outcomes. Patients will be monitored closely to assess the effectiveness of this targeted approach.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with autoimmune diseases, particularly those with IgG4-related disease.
Not a fit: Patients with autoimmune conditions not related to IgG4 or those who do not respond to immune-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with autoimmune diseases, potentially improving their quality of life.
How similar studies have performed: Previous research has shown success with similar approaches in targeting immune cells for autoimmune diseases, indicating a promising avenue for treatment.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Stone, John H — Massachusetts General Hospital
- Study coordinator: Stone, John H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.